- Home
- CURV vs KZIA Comparison
CURV vs KZIA Comparison
Compare CURV & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURV | KZIA |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | Australia |
| Employees | N/A | 6 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.9M | 186.7M |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CURV | KZIA |
|---|---|---|
| Price | $2.25 | $11.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $1.59 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 396.3K | 263.3K |
| Earning Date | 06-04-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,000,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $4.86 |
| 52 Week High | $2.86 | $17.40 |
Technical Indicators
Market Signals| Indicator | CURV | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 38.77 |
| Support Level | $1.02 | $7.25 |
| Resistance Level | $2.86 | $14.85 |
| Average True Range (ATR) | 0.18 | 1.15 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 27.50 | 5.04 |
Price Performance
Historical ComparisonAbout CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.